390 related articles for article (PubMed ID: 18611061)
21. Renin inhibition in hypertension.
Gradman AH; Kad R
J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
Gradman AH; Traub D
Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
[TBL] [Abstract][Full Text] [Related]
23. Aliskiren: renin inhibitor for hypertension management.
Cheng JW
Clin Ther; 2008 Jan; 30(1):31-47. PubMed ID: 18343241
[TBL] [Abstract][Full Text] [Related]
24. New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren.
Ichihara A; Sakoda M; Kurauchi-Mito A; Narita T; Kinouchi K; Bokuda K; Itoh H
J Pharmacol Sci; 2010; 113(4):296-300. PubMed ID: 20675959
[TBL] [Abstract][Full Text] [Related]
25. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
[TBL] [Abstract][Full Text] [Related]
26. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
27. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
[TBL] [Abstract][Full Text] [Related]
28. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.
Sureshkumar KK
Vasc Health Risk Manag; 2008; 4(6):1205-20. PubMed ID: 19337534
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Sica D; Gradman AH; Lederballe O; Kolloch RE; Zhang J; Keefe DL
Clin Drug Investig; 2011 Dec; 31(12):825-37. PubMed ID: 22035463
[TBL] [Abstract][Full Text] [Related]
31. Aliskiren in the management of hypertension.
Barrios V; Escobar C
Am J Cardiovasc Drugs; 2010; 10(6):349-58. PubMed ID: 21090828
[TBL] [Abstract][Full Text] [Related]
32. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
33. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
34. Current concepts: renin inhibition in the treatment of hypertension.
Gradman AH; Pinto R; Kad R
Curr Opin Pharmacol; 2008 Apr; 8(2):120-6. PubMed ID: 18308634
[TBL] [Abstract][Full Text] [Related]
35. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension.
Duggan ST; Chwieduk CM; Curran MP
Drugs; 2010 Oct; 70(15):2011-49. PubMed ID: 20883056
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
[TBL] [Abstract][Full Text] [Related]
37. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
39. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
40. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
